Skip to content

Bicara Therapeutics BCAX Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$3.47B-351%
Amgen logo
AmgenAMGN
$1.44B+135%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$54.87M+712%
Immunome logo
ImmunomeIMNM
-$135K-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M-97.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$7.92M+751%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's financing cash flow?
Bicara Therapeutics (BCAX) reported financing cash flow of $163.35M in Q1 2026.
How has Bicara Therapeutics's financing cash flow changed year-over-year?
Bicara Therapeutics's financing cash flow increased by 35409.8% year-over-year, from $460K to $163.35M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.